Results 191 to 200 of about 754,363 (313)

Hepatitis B: Are You At Risk? (Khmer)

Read the hepatitis B fact sheet in ...

core  

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Liver Int
Alhalabi M, Alshiekh HA.
europepmc   +1 more source

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug‐Resistant Tuberculosis

Clinical Pharmacology &Therapeutics, EarlyView.
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell, Antonio Lombardi, William Brumskine, Lali Mikiashvili, Kim Boekelheide, Joanna Moreira, Alda Holsta, Matthew Betteridge, Lindsay Thompson, Angela Crook, Paul Bruinenberg, Maria Beumont, Eugene Sun, Francesca Conradie   +13 more
wiley   +1 more source

Determinants of Hepatitis B vaccine uptake among health science students: A cross-sectional study in <i>Burao</i>, Somaliland. [PDF]

Hum Vaccin Immunother
Yousuf HJ, Farah AA, Hussein AA, Egeh MH, Omer AA, Mohamoud BM, Ahmed SA.   +6 more
europepmc   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Expression of mutant TIE2 p.L914F during mouse development causes embryonic lethality and defects in vascular remodeling

Developmental Dynamics, EarlyView.
Abstract Background Sporadic venous malformation (VM) is associated with the hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development. This mutation is not found in hereditary VM, suggesting incompatibility with life when expressed during early vascular development.
Lindsay J. Bischoff, Sandra Schrenk, Kara Soroko, Chhiring Sherpa, Ashok Arasu, Damien Reynaud, Elisa Boscolo   +6 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma. [PDF]

World J Biol Chem
Abdulrahman MS, Aboelmagd O, Zhang Y, Zaky S, Johar D.   +4 more
europepmc   +1 more source